Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–11.

CAS  PubMed  PubMed Central  Google Scholar 

Bhoopathi P, Mannangatti P, Emdad L, Das SK, Fisher PB. The quest to develop an effective therapy for neuroblastoma. J Cell Physiol. 2021;236(11):7775–91.

CAS  PubMed  Google Scholar 

Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022;19(8):515–33.

CAS  PubMed  Google Scholar 

Herd F, Basta NO, McNally RJQ and Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer (Oxford, England : 1990). 2019;111:50–58.

Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979–2015. Paediatr Drugs. 2017;19(6):577–93.

PubMed  PubMed Central  Google Scholar 

Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma Lancet. 2007;369(9579):2106–20.

Gai W, Peng Z, Liu CH, Zhang L, Jiang H. Advances in cancer treatment by targeting the neddylation pathway. Frontiers in cell and developmental biology. 2021;9: 653882.

PubMed  PubMed Central  Google Scholar 

Liu D, Che X, Wu G. Deciphering the role of neddylation in tumor microenvironment modulation: common outcome of multiple signaling pathways. Biomarker research. 2024;12(1):5.

PubMed  PubMed Central  Google Scholar 

Tian Z, Li J, Ma R, Li T, Sun Z, Huang S. Targeting neddylation as a novel approach to lung cancer treatment (Review). International journal of oncology. 2023;62(5):65.

CAS  PubMed  PubMed Central  Google Scholar 

Paccez JD, Foret CLM, de Vasconcellos JF, Donaldson L, Zerbini LF. DCUN1D1 and neddylation: potential targets for cancer therapy. Biochim Biophys Acta Mol Basis Dis. 2024;1870(7):167308.

CAS  PubMed  Google Scholar 

Xu J, Ye Z, Zhuo Q, Gao H, Qin Y, Lou X, Zhang W, Wang F, Wang Y, Jing D, Fan G, Zhang Y, Chen X, Chen J, Xu X, Yu X, Ji S. MEN1 degradation induced by neddylation and the CUL4B-DCAF7 axis promotes pancreatic neuroendocrine tumor progression. Cancer Res. 2023;83(13):2226–47.

CAS  PubMed  Google Scholar 

Huang X, Yi P, Gou W, Zhang R, Wu C, Liu L, He Y, Jiang X, Feng J. Neddylation signaling inactivation by tetracaine hydrochloride suppresses cell proliferation and alleviates vemurafenib-resistance of melanoma. Cell Biol Toxicol. 2024;40(1):81.

CAS  PubMed  PubMed Central  Google Scholar 

Guo YJ, Pang JR, Zhang Y, Li ZR, Zi XL, Liu HM, Wang N, Zhao LJ, Gao Y, Wang B, Herdewijn P, Jin CY, Liu Y, Zheng YC. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer. Int J Biol Macromol. 2024;254(Pt 3):126801.

CAS  PubMed  Google Scholar 

Dong R, Yang R, Zhan Y, Lai HD, Ye CJ, Yao XY, Luo WQ, Cheng XM, Miao JJ, Wang JF, Liu BH, Liu XQ, Xie LL, Li Y, Zhang M, Chen L, Song WC, Qian W, Gao WQ, Tang YH, Shen CY, Jiang W, Chen G, Yao W, Dong KR, Xiao XM, Zheng S, Li K, Wang J. Single-cell characterization of malignant phenotypes and developmental trajectories of adrenal neuroblastoma. Cancer Cell. 2020;38(5):716-33.e6.

CAS  PubMed  Google Scholar 

Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–62.

CAS  PubMed  Google Scholar 

Xu J, Li L, Yu G, Ying W, Gao Q, Zhang W, Li X, Ding C, Jiang Y, Wei D, Duan S, Lei Q, Li P, Shi T, Qian X, Qin J, Jia L. The neddylation-cullin 2-RBX1 E3 ligase axis targets tumor suppressor RhoB for degradation in liver cancer. Mol Cell Proteomics. 2015;14(3):499–509.

CAS  PubMed  Google Scholar 

Sun J, Liu C, Lang C, Wang J, Li Q, Peng C, Du Z, Chen Y, Huang P. Inhibiting neddylation: a new strategy for tumor therapy. J Pharm Anal. 2025;15(5):101140.

PubMed  Google Scholar 

Enchev RI, Schulman BA, Peter M. Protein neddylation: beyond cullin-RING ligases. Nat Rev Mol Cell Biol. 2015;16(1):30–44.

CAS  PubMed  PubMed Central  Google Scholar 

Seeler JS, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017;17(3):184–97.

CAS  PubMed  Google Scholar 

Xie P, Peng Z, Chen Y, Li H, Du M, Tan Y, Zhang X, Lu Z, Cui CP, Liu CH, He F, Zhang L. Neddylation of PTEN regulates its nuclear import and promotes tumor development. Cell Res. 2021;31(3):291–311.

CAS  PubMed  Google Scholar 

Bellini A, Pötschger U, Bernard V, Lapouble E, Baulande S, Ambros PF, Auger N, Beiske K, Bernkopf M, Betts DR, Bhalshankar J, Bown N, de Preter K, Clément N, Combaret V, Font de Mora J, George SL, Jiménez I, Jeison M, Marques B, Martinsson T, Mazzocco K, Morini M, Mühlethaler-Mottet A, Noguera R, Pierron G, Rossing M, Taschner-Mandl S, Van Roy N, Vicha A, Chesler L, Balwierz W, Castel V, Elliott M, Kogner P, Laureys G, Luksch R, Malis J, Popovic-Beck M, Ash S, Delattre O, Valteau-Couanet D, Tweddle DA, Ladenstein R, Schleiermacher G. Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). J Clin Oncol: Off J Am Soc Clin Oncol. 2021;39(30):3377–90.

CAS  Google Scholar 

Oberthuer A, Juraeva D, Hero B, Volland R, Sterz C, Schmidt R, Faldum A, Kahlert Y, Engesser A, Asgharzadeh S, Seeger R, Ohira M, Nakagawara A, Scaruffi P, Tonini GP, Janoueix-Lerosey I, Delattre O, Schleiermacher G, Vandesompele J, Speleman F, Noguera R, Piqueras M, Bénard J, Valent A, Avigad S, Yaniv I, Grundy RG, Ortmann M, Shao C, Schwab M, Eils R, Simon T, Theissen J, Berthold F, Westermann F, Brors B, Fischer M. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers. Clin Cancer Res. 2015;21(8):1904–15.

PubMed  Google Scholar 

Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;1(470):126–33.

Google Scholar 

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.

CAS  PubMed  PubMed Central  Google Scholar 

Álvarez-Carrasco P, Maldonado-Bernal C. The innate defenders: a review of natural killer cell immunotherapies in cancer. Front Immunol. 2024;15:1482807.

PubMed  PubMed Central  Google Scholar 

Nikkhoi SK, Li G, Hatefi A. Natural killer cell engagers for cancer immunotherapy. Front Oncol. 2024;14:1483884.

CAS  PubMed  Google Scholar 

Alam MR, Akinyemi AO, Wang J, Howlader M, Farahani ME, Nur M, Zhang M, Gu L, Li Z. CD4(+)CD8(+) double-positive T cells in immune disorders and cancer: prospects and hurdles in immunotherapy. Autoimmun Rev. 2025;24(3):103757.

CAS  PubMed  Google Scholar 

Zhang B, Liu J, Mo Y, Zhang K, Huang B, Shang D. CD8(+) T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy. Front Immunol. 2024;15:1476904.

CAS  PubMed  PubMed Central  Google Scholar 

Rishabh K, Matosevic S. The diversity of natural killer cell functional and phenotypic states in cancer. Cancer Metastasis Rev. 2025;44(1):26.

PubMed  Google Scholar 

Ghasempour A, Mohseni R, Sharif PM, Hamidieh AA. Natural killer cell-based therapies in neuroblastoma. Cell Immunol. 2025;407:104898.

CAS  PubMed  Google Scholar 

Tao JH, Zhang J, Li HS, Zhou Y, Guan CX. Nature killer cell for solid tumors: current obstacles and prospective remedies in NK cell therapy and beyond. Crit Rev Oncol Hematol. 2025;205:104553.

PubMed  Google Scholar 

Aierken Y, Tan K, Liu T, Lv Z. Prognosis and immune infiltration prediction in neuroblastoma based on neutrophil extracellular traps-related gene signature. Sci Rep. 2025;15(1):5343.

CAS  PubMed  PubMed Central  Google Scholar 

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017;214(3):579–96.

PubMed  PubMed Central  Google Scholar 

Ielpo S, Barberini F, Dabbagh Moghaddam F, Pesce S, Cencioni C, Spallotta F, De Ninno A, Businaro L, Marcenaro E, Bei R, Cifaldi L, Barillari G, Melaiu O. Crosstalk and communication of cancer-associated fibroblasts with natural killer and dendritic cells: new frontiers and unveiled opportunities for cancer immunotherapy. Cancer Treat Rev. 2024;131:102843.

CAS  PubMed  Google Scholar 

Song J, Wei R, Liu C, Zhao Z, Liu X, Wang Y, Liu F, Liu X. Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response. Nat Commun. 2025;16(1):2175.

CAS  PubMed  PubMed Central  Google Scholar 

David CJ, Huang YH, Chen M, Su J, Zou Y, Bardeesy N, Iacobuzio-Donahue CA, Massagué J. TGF-β Tumor suppression through a lethal EMT. Cell. 2016;164(5):1015–30.

CAS  PubMed  PubMed Central